Skip to main content
SpringerLink
Log in

Serum Free Light Chain Analysis

  • Chapter
  • First Online:
Plasma Cell Neoplasms

Abstract

In healthy individuals, plasma cells originating from the bone marrow produce immunoglobulin molecules composed of two heavy chains and two light chains. There are two types of light chains in humans, kappa and lambda. The chapter provides an overview of the history, utility and interpretation of free light chain (FLC) measurement in plasma cell dyscrasias.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Janeway CA Jr, Travers P, Walport M, Shlomchik MJ. Immunobiology. 5th edn. New York: Garland Publishing; 2001.

    Google Scholar 

  2. Solomon A. Light chains of human immunoglobulins. Methods Enzymol. 1985;116:101–21.

    Article  CAS  PubMed  Google Scholar 

  3. Batuman V, Verroust PJ, Navar GL, Kaysen JH, Goda FO, Campbell WC, et al. Myeloma light chains are ligands for cubilin (gp280). Am J Physiol. 1998;275(2 Pt 2):F246–54.

    Google Scholar 

  4. Rennke HG, Denker BM. Renal pathophysiology: the essentials. Philadelphia: Wolters Kluwer; 2013 (Chapter 10 p).

    Google Scholar 

  5. Katzmann JA, Kyle RA, Benson J, Larson DR, Snyder MR, Lust JA, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem. 2009;55(8):1517–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Ying WZ, Sanders PW. Mapping the binding domain of immunoglobulin light chains for Tamm–Horsfall protein. Am J Pathol. 2001;158(5):1859–66.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Sanders PW, Booker BB, Bishop JB, Cheung HC. Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. J Clin Invest. 1990;85(2):570–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Sanders PW, Booker BB. Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest. 1992;89(2):630–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Jones HB. Papers on chemical pathology. Lancet. 1847(lecture III).

    Google Scholar 

  11. Macintyre W. Case of mollities and fragilitas ossium, accompanied with urine strongly charged with animal matter. Med Chir Trans. 1850;33:211–32.

    PubMed Central  CAS  PubMed  Google Scholar 

  12. Bladé J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am. 1999;13(6):1259–72.

    Article  PubMed  Google Scholar 

  13. Solomon A, Waldmann TA, Fahey JL, Mcfarlane AS. Metabolism of Bence Jones proteins. J Clin Invest. 1964;43:103–17.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Nowrousian MR, Brandhorst D, Sammet C, Kellert M, Daniels R, Schuett P, et al. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res. 2005; 11(24 Pt 1):8706–14.

    Article  CAS  PubMed  Google Scholar 

  15. Hill PG, Forsyth JM, Rai B, Mayne S. Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies. Clin Chem. 2006;52(9):1743–8.

    Article  CAS  PubMed  Google Scholar 

  16. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215–24.

    Article  CAS  PubMed  Google Scholar 

  17. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem. 2001;47(4):673–80.

    CAS  PubMed  Google Scholar 

  18. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48(9):1437–44.

    CAS  PubMed  Google Scholar 

  19. Waldmann TA, Strober W, Mogielnicki RP. The renal handling of low molecular weight proteins. II. Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia. J Clin Invest. 1972;51(8):2162–74.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Miettinen TA, Kekki M. Effect of impaired hepatic and renal function on 131 Bence Jones protein catabolism in human subjects. Clin ChimActa. 1967;18(3):395–407.

    Article  Google Scholar 

  21. Wochner RD, Strober W, Waldmann TA. The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments. J Exp Med. 1967;126(2):207–21.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(6):1684–90.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Hutchison CA, Cockwell P, Harding S, Mead GP, Bradwell AR, Barnett AH. Quantitative assessment of serum and urinary polyclonal free light chains in patients with type II diabetes: an early marker of diabetic kidney disease? Expert Opin Ther Targets. 2008;12(6):667–76.

    Article  CAS  PubMed  Google Scholar 

  24. Piehler AP, Gulbrandsen N, Kierulf P, Urdal P. Quantitation of serum free light chains in combination with protein electrophoresis and clinical information for diagnosing multiple myeloma in a general hospital population. Clin Chem. 2008;54(11):1823–30.

    Article  CAS  PubMed  Google Scholar 

  25. Vermeersch P, Van Hoovels L, Delforge M, Mariën G, Bossuyt X. Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal B-cell disorder. Br J Haematol. 2008;143(4):496–502.

    PubMed  Google Scholar 

  26. Jenner E. Serum free light chains in clinical laboratory diagnostics. Clin Chim Acta. 2014;427:15–20.

    Article  CAS  PubMed  Google Scholar 

  27. Tate J, Bazeley S, Sykes S, Mollee P. Quantitative serum free light chain assay—analytical issues. Clin Biochem Rev. 2009;30(3):131–40.

    PubMed Central  PubMed  Google Scholar 

  28. te Velthuis H, Knop I, Stam P, van den Broek M, Bos HK, Hol S, et al. N Latex FLC—new monoclonal high-performance assays for the determination of free light chain kappa and lambda. Clin Chem Lab Med. 2011;49(8):1323–32.

    Article  Google Scholar 

  29. Davern S, Tang LX, Williams TK, Macy SD, Wall JS, Weiss DT, et al. Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies. Am J Clin Pathol. 2008;130(5):702–11.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Nakano T, Miyazaki S, Takahashi H, Matsumori A, Maruyama T, Komoda T, et al. Immunochemical quantification of free immunoglobulin light chains from an analytical perspective. Clin Chem Lab Med. 2006;44(5):522–32.

    Article  CAS  PubMed  Google Scholar 

  31. Pretorius CJ, Klingberg S, Tate J, Wilgen U, Ungerer JP. Evaluation of the N Latex FLC free light chain assay on the Siemens BN analyser: precision, agreement, linearity and variation between reagent lots. Ann Clin Biochem. 2012;49(Pt 5):450–5.

    Article  CAS  PubMed  Google Scholar 

  32. Tate JR, Gill D, Cobcroft R, Hickman PE. Practical considerations for the measurement of free light chains in serum. Clin Chem. 2003;49(8):1252–7.

    Article  CAS  PubMed  Google Scholar 

  33. Hansen CT, Münster AM, Nielsen L, Pedersen P, Abildgaard N. Clinical and preclinical validation of the serum free light chain assay: identification of the critical difference for optimized clinical use. Eur J Haematol. 2012;89(6):458–68.

    Article  CAS  PubMed  Google Scholar 

  34. Le Bricon T Bengoufa D Benlakehal M Bousquet B Erlich D. Urinary free light chain analysis by the Freelite immunoassay: a preliminary study in multiple myeloma. Clin Biochem. 2002;35(7):565–7.

    Article  CAS  PubMed  Google Scholar 

  35. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet. 2003;361(9356):489–91.

    Article  PubMed  Google Scholar 

  36. Bhole MV, Sadler R Ramasamy K. Serum-free light-chain assay: clinical utility and limitations. Ann Clin Biochem. 2014;51(Pt 5):528–42.

    Google Scholar 

  37. Campbell JP, Cobbold M, Wang Y, Goodall M, Bonney SL, Chamba A, et al. Development of a highly-sensitive multiplex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine. J Immunol Methods. 2013;391(1–2):1–13.

    Article  CAS  PubMed  Google Scholar 

  38. Hutchison CA, Plant T, Drayson M, Cockwell P, Kountouri M, Basnayake K, et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol. 2008;9:11.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Rajkumar SV, Kyle RA, Therneau TM, Clark RJ, Bradwell AR, Melton LJ, et al. Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance. Br J Haematol. 2004;127(3):308–10.

    Article  CAS  PubMed  Google Scholar 

  40. Katzmann JA, Dispenzieri A, Kyle RA, Snyder MR, Plevak MF, Larson DR, et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc. 2006;81(12):1575–8.

    Article  CAS  PubMed  Google Scholar 

  41. Rajkumar SV, Kyle RA, Therneau TM, Melton LJ, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106(3):812–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, et al. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood. 2013;122(26):4172–81.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. McTaggart MP, Lindsay J, Kearney EM. Replacing urine protein electrophoresis with serum free light chain analysis as a first-line test for detecting plasma cell disorders offers increased diagnostic accuracy and potential health benefit to patients. Am J Clin Pathol. 2013;140(6):890–7.

    Article  PubMed  Google Scholar 

  44. Altinier S, Seguso M, Zaninotto M, Varagnolo M, Adami F, Angeli P, et al. Serum free light chain reference values: a critical approach. Clin Biochem. 2013;46(7–8):691–3.

    Article  CAS  PubMed  Google Scholar 

  45. Pattenden RJ, Rogers SY, Wenham PR. Serum free light chains; the need to establish local reference intervals. Ann Clin Biochem. 2007;44(Pt 6):512–5.

    Article  CAS  PubMed  Google Scholar 

  46. Pratt G. The evolving use of serum free light chain assays in haematology. Br J Haematol. 2008;141(4):413–22.

    Article  CAS  PubMed  Google Scholar 

  47. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564–9.

    Article  PubMed  Google Scholar 

  48. Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111(2):785–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2006;107(8):3378–83.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. Dingli D, Kyle RA, Rajkumar SV, Nowakowski GS, Larson DR, Bida JP, et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood. 2006;108(6):1979–83.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  51. Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, Sachanas S, Tzenou T, Papadogiannis A, et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol. 2007;137(3):240–3.

    Article  CAS  PubMed  Google Scholar 

  52. Hutchison CA, Bladé J, Cockwell P, Cook M, Drayson M, Fermand JP, et al. Novel approaches for reducing free light chains in patients with myeloma kidney. Nat Rev Nephrol. 2012;8(4):234–43.

    Article  CAS  PubMed  Google Scholar 

  53. Hutchison CA, Batuman V, Behrens J, Bridoux F, Sirac C, Dispenzieri A, et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol. 2012;8(1):43–51.

    Article  CAS  Google Scholar 

  54. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–73.

    Article  CAS  PubMed  Google Scholar 

  55. Dispenzieri A, Zhang L, Katzmann JA, Snyder M, Blood E, Degoey R, et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood. 2008;111(10):4908–15.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  56. Sheldon J. Free light chains. Ann Clin Biochem. 2007;44(Pt 6):503–5.

    Article  PubMed  Google Scholar 

  57. Lock RJ, Saleem R, Roberts EG, Wallage MJ, Pesce TJ, Rowbottom A, et al. A multicentre study comparing two methods for serum free light chain analysis. Ann Clin Biochem. 2013;50(Pt 3):255–61.

    Article  CAS  PubMed  Google Scholar 

  58. Drayson M. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood. 2001;97(9):2900–2.

    Article  CAS  PubMed  Google Scholar 

  59. Abraham RS, Charlesworth MC, Owen BA, Benson LM, Katzmann JA, Reeder CB, et al. Trimolecular complexes of lambda light chain dimers in serum of a patient with multiple myeloma. Clin Chem. 2002;48(10):1805–11.

    CAS  PubMed  Google Scholar 

  60. Murata K, Clark RJ, Lockington KS, Tostrud LJ, Greipp PR, Katzmann JA. Sharply increased serum free light-chain concentrations after treatment for multiple myeloma. Clin Chem. 2010;56(1):16–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine and Pathology, University of Minnesota, 420 Delaware St. SE, MMC 609, 55454, Minneapolis, MN, USA

    Rajeevan Selvaratnam PhD, Jing Cao PhD & Amy B. Karger MD, PhD

Authors
  1. Rajeevan Selvaratnam PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jing Cao PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amy B. Karger MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amy B. Karger MD, PhD .

Editor information

Editors and Affiliations

  1. and Pathology, University of Minnesota Department of Laboratory Medicine, Minneapolis, Minnesota, USA

    Michael A. Linden

  2. and Pathology, University of Minnesota Department of Laboratory Medicine, Minneapolis, Minnesota, USA

    Robert W. McKenna

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Selvaratnam, R., Cao, J., Karger, A. (2016). Serum Free Light Chain Analysis. In: Linden, M., McKenna, R. (eds) Plasma Cell Neoplasms. Springer, Cham. https://doi.org/10.1007/978-3-319-10918-3_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-10918-3_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-10917-6

  • Online ISBN: 978-3-319-10918-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation